Chronic inflammatory skin diseases like psoriasis, hidradenitis suppurativa, atopic dermatitis, and alopecia areata are now recognized as significant risk factors for cardiovascular disease. Meanwhile, cardiovascular conditions—like infective endocarditis, heart failure, and thromboembolism—can present with key skin findings that aid in diagnosis. This session explores the bidirectional relationship between skin and heart health, highlighting how therapies in one domain can impact the other, and emphasizes the need for interdisciplinary awareness. Despite growing evidence, clear screening guidelines for cardiovascular risk in dermatologic patients remain limited, making education and early recognition essential for improving outcomes.

Sponsored by Arcutis Biotherapeutics, Inc.

Psoriasis is a chronic autoimmune disease that affects approximately 8 million people in the US and places a substantial physical, psychological, and social burden on patients. [i]Despite therapeutic advances, management remains difficult due to poor adherence and patient dissatisfaction with current options. Injectable biologics offer durable control but are often limited by barriers such as injection fatigue, needle aversion, and costs. Oral therapies provide a convenient alternative by targeting systemic inflammation without injections. This session will appropriately position these therapies by comparing efficacy and safety across oral and injectable agents, and outline strategies for determining which patients are most likely to benefit from oral versus injectable approaches. After participating in this educational initiative, learners should be able to: • Examine limitations of injectable biologics in psoriasis, including barriers to adherence and patient preference for non-injectable options • Assess the safety/efficacy data and mechanisms of action of current and emerging oral therapies for moderate-to-severe PsO, including head-to-head comparisons and long-term data • Identify strategies to determine when patients may benefit from oral versus injectable treatment approaches Supported by an educational grant from Johnson & Johnson.

Sponsored by Sun Pharmaceutics, Inc.

Join a panel of leading dermatology experts for a dynamic, interactive Q&A session addressing the most pressing questions facing today’s dermatology practices. This session will focus on real-world clinical challenges, emerging trends, and practical strategies to optimize patient care, practice efficiency, and clinical decision-making. Attendees will have the opportunity to engage directly with faculty, gain expert insights on controversial and evolving topics, and leave with actionable takeaways they can immediately apply in practice on Monday.

The evolving concept of remission in dermatology is reshaping clinical expectations and research strategies. Recently, the National Psoriasis Foundation introduced a distinction between on-drug remission and off-drug remission. The International Eczema Council is working on similar distinctions. Faculty will discuss these new concepts that continue to gain traction as standards in research and practice.

Sponsored by Regeneron Pharmaceuticals, Inc.

Psoriasis is a chronic autoimmune disease that affects approximately 8 million people in the US and places a substantial physical, psychological, and social burden on patients. [i]Despite therapeutic advances, management remains difficult due to poor adherence and patient dissatisfaction with current options. Injectable biologics offer durable control but are often limited by barriers such as injection fatigue, needle aversion, and costs. Oral therapies provide a convenient alternative by targeting systemic inflammation without injections. This session will appropriately position these therapies by comparing efficacy and safety across oral and injectable agents, and outline strategies for determining which patients are most likely to benefit from oral versus injectable approaches. After participating in this educational initiative, learners should be able to: • Examine limitations of injectable biologics in psoriasis, including barriers to adherence and patient preference for non-injectable options • Assess the safety/efficacy data and mechanisms of action of current and emerging oral therapies for moderate-to-severe PsO, including head-to-head comparisons and long-term data • Identify strategies to determine when patients may benefit from oral versus injectable treatment approaches Supported by an educational grant from Johnson & Johnson.

SUN Pharmaceuticals Industries Limited.

Join a panel of leading dermatology experts for a dynamic, interactive Q&A session addressing the most pressing questions facing today’s dermatology practices. This session will focus on real-world clinical challenges, emerging trends, and practical strategies to optimize patient care, practice efficiency, and clinical decision-making. Attendees will have the opportunity to engage directly with faculty, gain expert insights on controversial and evolving topics, and leave with actionable takeaways they can immediately apply in practice on Monday.

Despite advances in Th2- and JAK/STAT-targeted therapies, many patients with atopic dermatitis (AD) continue to experience residual symptoms, especially pruritus. New approaches are exploring IL-31 inhibition and refined JAK-STAT modulation to address persistent itch, particularly in “clear-skin, persistent-itch” phenotypes. Additional targets include TSLP, IL-1 family cytokines, OX40/OX40L, and Th17/Th22 pathways. Adjunctive device-based modalities—such as phototherapy, transcutaneous electrical nerve stimulation, and cold plasma therapy—are also under investigation. This session will provide an overview of these next-generation therapies.

Sponsored by SUN Pharmaceuticals Industries Limited.

Cutaneous lupus erythematosus (CLE) is an interferon-driven autoimmune skin disease with three main subtypes—acute (ACLE), subacute (SCLE), and chronic (CCLE), including discoid lupus erythematosus and related variants. Overlap with systemic lupus erythematosus (SLE) and other dermatologic conditions complicates diagnosis and management, underscoring the importance of early recognition to prevent irreversible damage. Conventional treatments are often nonspecific, slow to act, and limited by tolerability and monitoring concerns, whereas emerging targeted therapies show promise. Given its chronic, relapsing course, optimized outcomes require multidisciplinary care and continued clinician education to improve diagnosis, treatment, and patient quality of life. After participating in this educational initiative, learners should be able to: • Describe the pathogenesis, clinical variations, and diagnosis of acute, subacute, and chronic CLE to support comprehensive assessment and timely treatment • Evaluate current clinical data associated with available and emerging treatment options for CLE • Implement evidence-based and individualized CLE care that incorporates an interdisciplinary approach to management Supported by an educational grant from Biogen.

Sponsored by Arcutis Biotherapeutics, Inc.

Join a panel of leading dermatology experts for a dynamic, interactive Q&A session addressing the most pressing questions facing today’s dermatology practices. This session will focus on real-world clinical challenges, emerging trends, and practical strategies to optimize patient care, practice efficiency, and clinical decision-making. Attendees will have the opportunity to engage directly with faculty, gain expert insights on controversial and evolving topics, and leave with actionable takeaways they can immediately apply in practice on Monday.

Be prepared for anything after this session, which will discuss recent advances in hidradenitis suppurativa treatments. Biologic therapies and small-molecule drugs have expanded treatment options by targeting key components of the disease's immunopathogenesis. Biologics, including TNF-α inhibitors and interleukin-targeting agents, have demonstrated efficacy in reducing inflammation, abscess formation, and disease progression, while improving quality of life. Meanwhile, small-molecule therapies offer advantages such as oral delivery, novel intracellular targets, and immune modulation. Ongoing research is optimizing the use of these agents, exploring their long-term outcomes, and investigating combination approaches.

Sponsored by Regeneron Pharmaceuticals Inc.

These highly interactive educational sessions offer a comprehensive and practical look into a diverse array of dermatologic conditions. With a focus on translating current research into practical, real-world applications, these sessions will help you to effectively integrate the latest advances in dermatologic care into clinical practice, enhancing your professional skills and improving patient outcomes. Both seasoned and early-career dermatology professionals will benefit from these educational grant–supported sessions. Applications for commercial support from healthcare-related industries are pending. Commercial support will be acknowledged as it is received.

Sponsored by Eli Lilly and Company.

Join a panel of leading dermatology experts for a dynamic, interactive Q&A session addressing the most pressing questions facing today’s dermatology practices. This session will focus on real-world clinical challenges, emerging trends, and practical strategies to optimize patient care, practice efficiency, and clinical decision-making. Attendees will have the opportunity to engage directly with faculty, gain expert insights on controversial and evolving topics, and leave with actionable takeaways they can immediately apply in practice on Monday.

Join leading dermatology experts for an engaging discussion on the prevention and treatment of hyperpigmentation, one of the most common and challenging concerns in clinical practice. Faculty will share practical approaches to early intervention, individualized treatment selection, and patient counseling, while exploring the roles of topical, oral, and procedural therapies. The conversation will also highlight the evolving science of photoprotection, strategies for managing refractory cases, and emerging advances that may reshape care. Designed to provide real-world insights and actionable clinical pearls, this session will equip attendees with practical strategies to improve outcomes for patients with hyperpigmentation.

Psoriatic arthritis is a complex, multisystem inflammatory disease that requires individualized treatment to address diverse clinical manifestations and comorbidities. This session reviews the immunologic pathways driving PsA and the mechanisms of action of current biologic therapies. Faculty will examine emerging clinical trial data and practical considerations for comparing treatment options. Attendees will gain evidence-based strategies for selecting biologic therapies using a treat-to-target approach to improve long-term patient outcomes. This activity is supported through an independent educational grant from UCB.

Join a panel of leading dermatology experts for a dynamic, interactive Q&A session addressing the most pressing questions facing today’s dermatology practices. This session will focus on real-world clinical challenges, emerging trends, and practical strategies to optimize patient care, practice efficiency, and clinical decision-making. Attendees will have the opportunity to engage directly with faculty, gain expert insights on controversial and evolving topics, and leave with actionable takeaways they can immediately apply in practice on Monday.

Join experts in skin of color dermatology for a practical discussion on the diagnosis and management of inflammatory scalp conditions in diverse patient populations. Faculty will explore the unique clinical presentation of common scalp disorders, including seborrheic dermatitis, scalp psoriasis, central centrifugal cicatricial alopecia, and traction alopecia, while addressing the influence of hair texture and cultural hair care practices on diagnosis and treatment. The discussion will highlight evidence-based management strategies, culturally responsive patient counseling, and practical approaches to improving treatment adherence and long-term outcomes for patients with inflammatory scalp disease.

Sponsored by Arcutis Biotherapeutics, Inc.

Pediatric atopic dermatitis is a common chronic inflammatory skin disease that can significantly affect quality of life for children and their caregivers. This session reviews current approaches to diagnosis and disease assessment while addressing the challenges of managing diverse clinical presentations across age groups and skin types. Faculty will discuss the evolving role of nonsteroidal topical therapies and strategies for integrating them into individualized treatment plans. Attendees will gain practical, evidence-based tools to optimize long-term disease control and improve patient outcomes. Learning Objectives • Apply current guideline-directed and evidence-based strategies to improve the recognition, diagnosis, and assessment of pediatric AD across diverse patient populations • Evaluate the safety, efficacy, indications, and appropriate clinical use of newer nonsteroidal topical therapies for pediatric AD • Employ individualized, patient-centered management for pediatric AD that incorporates shared decision-making with patients/caregivers and addresses diverse skin types and patient populations Supported by an educational grant from Arcutis Biotherapeutics, Inc.

Join a panel of leading dermatology experts for a dynamic, interactive Q&A session addressing the most pressing questions facing today’s dermatology practices. This session will focus on real-world clinical challenges, emerging trends, and practical strategies to optimize patient care, practice efficiency, and clinical decision-making. Attendees will have the opportunity to engage directly with faculty, gain expert insights on controversial and evolving topics, and leave with actionable takeaways they can immediately apply in practice on Monday.

Systemic mastocytosis is a rare, multisystem disorder with diverse clinical manifestations that can delay diagnosis and complicate management. This session reviews the cutaneous and systemic features of SM to support early recognition and appropriate diagnostic evaluation. Faculty will discuss current and emerging targeted therapies and their role in optimizing patient care. Attendees will gain practical strategies for coordinating multidisciplinary management to improve outcomes for patients with SM. Learning Objectives • Identify the cutaneous and systemic manifestations of SM using current guideline-based criteria to support appropriate initial evaluation and referral for systemic assessment • Differentiate the mechanisms of action, efficacy, and safety of approved and emerging targeted therapies for SM • Integrate multidisciplinary management strategies for patients with SM, including coordination across specialties and patient-centered, symptom-directed care Supported by an educational grant from Blueprint Medicines Corporation.

Join a panel of leading dermatology experts for a dynamic, interactive Q&A session addressing the most pressing questions facing today’s dermatology practices. This session will focus on real-world clinical challenges, emerging trends, and practical strategies to optimize patient care, practice efficiency, and clinical decision-making. Attendees will have the opportunity to engage directly with faculty, gain expert insights on controversial and evolving topics, and leave with actionable takeaways they can immediately apply in practice on Monday.

Join leading faculty for a lively discussion of the most impactful research and clinical updates presented at the European Academy of Dermatology and Venereology (EADV) Annual Meeting. Experts will highlight late-breaking data, emerging therapies, and evolving treatment strategies across key areas of dermatology, while offering perspective on how new evidence may influence clinical practice. Designed to distill the meeting's most relevant takeaways, this session will provide attendees with timely insights and practical pearls they can immediately apply to patient care.

These highly interactive educational sessions offer a comprehensive and practical look into a diverse array of dermatologic conditions. With a focus on translating current research into practical, real-world applications, these sessions will help you to effectively integrate the latest advances in dermatologic care into clinical practice, enhancing your professional skills and improving patient outcomes. Both seasoned and early-career dermatology professionals will benefit from these educational grant–supported sessions. Applications for commercial support from healthcare-related industries are pending. Commercial support will be acknowledged as it is received.

Join a panel of leading dermatology experts for a dynamic, interactive Q&A session addressing the most pressing questions facing today’s dermatology practices. This session will focus on real-world clinical challenges, emerging trends, and practical strategies to optimize patient care, practice efficiency, and clinical decision-making. Attendees will have the opportunity to engage directly with faculty, gain expert insights on controversial and evolving topics, and leave with actionable takeaways they can immediately apply in practice on Monday.

Join an open, podcast-style conversation with leading dermatology faculty as they discuss the latest research shaping the field and spotlight high-interest, underserved areas of clinical practice. In this informal, engaging format, faculty will share expert perspectives, real-world experiences, and honest insights into emerging data, controversies, and gaps in care. Designed to spark thoughtful dialogue, this session offers attendees a fresh, accessible look at cutting-edge science and underrepresented topics, with practical takeaways to inform patient care and future research.

These highly interactive educational sessions offer a comprehensive and practical look into a diverse array of dermatologic conditions. With a focus on translating current research into practical, real-world applications, these sessions will help you to effectively integrate the latest advances in dermatologic care into clinical practice, enhancing your professional skills and improving patient outcomes. Both seasoned and early-career dermatology professionals will benefit from these educational grant–supported sessions. Applications for commercial support from healthcare-related industries are pending. Commercial support will be acknowledged as it is received.

Join a panel of leading dermatology experts for a dynamic, interactive Q&A session addressing the most pressing questions facing today’s dermatology practices. This session will focus on real-world clinical challenges, emerging trends, and practical strategies to optimize patient care, practice efficiency, and clinical decision-making. Attendees will have the opportunity to engage directly with faculty, gain expert insights on controversial and evolving topics, and leave with actionable takeaways they can immediately apply in practice on Monday.